These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12403640)

  • 1. Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery?
    Smith D; Schmid E; Jones B
    Clin Pharmacokinet; 2002; 41(13):1005-19. PubMed ID: 12403640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical predictions of drug absorption in drug discovery and development.
    Stenberg P; Bergström CA; Luthman K; Artursson P
    Clin Pharmacokinet; 2002; 41(11):877-99. PubMed ID: 12190333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New horizons in drug metabolism, pharmacokinetics and drug discovery.
    Palmer AM
    Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using in vitro human tissues to predict pharmacokinetic properties.
    Huebert ND; Dasgupta M; Chen Y
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early ADME in support of drug discovery: the role of metabolic stability studies.
    Thompson TN
    Curr Drug Metab; 2000 Nov; 1(3):215-41. PubMed ID: 11465046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution.
    Henchoz Y; Bard B; Guillarme D; Carrupt PA; Veuthey JL; Martel S
    Anal Bioanal Chem; 2009 Jun; 394(3):707-29. PubMed ID: 19184676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics.
    Smith DA; Jones BC; Walker DK
    Med Res Rev; 1996 May; 16(3):243-66. PubMed ID: 8727426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolism and pharmacokinetics in drug discovery.
    Roberts SA
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):66-80. PubMed ID: 12613278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.